Previewing the Family Heart Global Summit, with Laurence Sperling, MD

The field of lipid management is in the midst of a renaissance period. Driven by advances in pathophysiology, which have, in turn, compelled further pharmacological discovery, practitioners have found themselves the beneficiaries of this new age in dyslipidemias.

Still, with this sheer level of knowledge and advancements happening in such an accelerated timeframe, these practitioners have been faced with the nearly insurmountable challenge of absorbing, processing, and applying all of these advancements in the real-world care of patients. Although much of this information is shared at large flagship meetings, such as the American College of Cardiology, the American Heart Association, and the European Society of Cardiology annual meetings, other hyper-focused meetings have seen a rise to prominence, with their value apparent now more than ever.

An example of 1 of these meetings is the Family Heart Foundation’s Family Heart Global Summit. With the 2024 meeting, which will take place from September 22 to 24, 2024 in Dallas, TX, boasting a pair of Nobel Laureates on the opening day’s agenda, the meeting’s theme of "The Golden Age of Lipid Lowering: From Innovation to Impact”, is a theme reflective of the rapidly evolving landscape of lipid management.

Chaired by leading subject matter experts in Christie Ballantyne, MD, Fatima Rodriguez, MD, MPH, and Laurence Sperling, MD, the meeting will feature 6 sessions spotlighting a variety of topics from technological innovation in healthcare, pediatric screening for dyslipidemias, lipoprotein(a), and changing LDL-C targets. To learn more about the meeting and the importance of the various sessions included, the editorial team of HCPLive Cardiology sat down with Sperling, Katz Professor in Preventive Cardiology and founder of the Emory Center for Heart Disease Prevention, for his perspective as meeting co-chair.

Sperling has no relevant disclosures to report.